Roche Announces Updates on Alecensa for Adjuvant Therapy in ALK-Positive Early-Stage Non-Small Cell Lung Cancer

TOKYO, October 18, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche issued a press release regarding results of a phase III clinical trial (ALINA study) for anti-cancer agent/ALK inhibitor Alecensa ® (alectinib) for adjuvant therapy in ALK-positive early-stage non-small cell lung cancer. Please refer to the link below for details of the press release: Roche’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer https://www.roche.com/media/releases/med-cor-2023-10-18

The release as fetched from its publisher. chugai-pharm.co.jp ↗